REGENERON PHARMACEUTICALS, INC. (REGN)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$2,970.6M
Cash & Equivalents
$1,078.9M
Quarterly Burn Rate
$65,812M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (7 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
AFLIBERCEPT
EYLEA HD |
APPROVED | Abdominal Pain Upper, Advanced Cutaneous Squamous Cell Carcinoma, Advanced Solid Tumors, Age Related Macular Degeneration, Allergic Conjunctivitis, Allergic Rhinitis, Allergies Food Milk, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Familial, Amyloidosis, Hereditary, Ascites, Asthma, Atherosclerotic Disease, Atopic Dermatitis, Atopic Keratoconjunctivitis, Cancer, Cancer/Squamous Cell Carcinoma of Skin, Carcinoma，Non-Small-Cell Lung, CHAPLE Disease, Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis Without Nasal Polyps, COPD (Chronic Obstructive Pulmonary Disease), Corneal Neovascularization, COVID-19, Cutaneous Squamous Cell Carcinoma, Dermal Hypersensitivity Reaction, Dermatitis Atopic, Diabetic Glomerulosclerosis, Diabetic Macular Edema, Diabetic Nephropathies, Dysbetalipoproteinemia (DBL), Eczema, Endometrial Cancer, Eosinophilic Duodenitis (EoD), Eosinophilic Esophagitis, Eosinophilic Gastritis (EoG), Eosinophilic Gastroenterit |
|
ATOLTIVIMAB, ODESIVIMAB, MAFTIVIMAB
INMAZEB |
APPROVED | — |
|
EVINACUMAB-DGNB
EVKEEZA |
APPROVED | — |
|
ALIROCUMAB
PRALUENT |
APPROVED | — |
|
POZELIMAB-BBFG
VEOPOZ |
APPROVED | — |
|
DUPILUMAB
DUPIXENT |
APPROVED | — |
|
CEMIPLIMAB-RWLC
LIBTAYO |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.